Education
About Us
Working with TipRanks
Follow Us
Talphera (TLPH)
NASDAQ:TLPH
TLPH Stock Chart & Stats
$1.30
-$0.04(-6.10%)
At close: 4:00 PM EST
$1.30
-$0.04(-6.10%)
Day’s Range― - ―
52-Week Range$0.38 - $1.57
Previous CloseN/A
Volume42.81K
Average Volume (3M)2.97M
Market Cap
$59.66M
Enterprise Value$15.60M
Total Cash (Recent Filing)$21.29M
Total Debt (Recent Filing)$6.50M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 05, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding46,609,620
10 Day Avg. Volume675,544
30 Day Avg. Volume2,969,035
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue557.10
Enterprise Value/Gross Profit-6.33
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$3.25Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNiyad, the nafamostat-based anticoagulant being developed by Talphera, has been evaluated extensively overseas and was found to be efficacious and safe, supporting its development.
FinancingThe recent capital raise removes the financing overhang regarding Talphera’s ability to complete the Phase 3 trial and modestly de-risks the company.
Investment OpportunityThe financing establishes an attractive exit opportunity for Talphera shareholders, with the potential acquisition by CorMedix following the primary endpoint readout.
Bears Say
Enrollment DelaysSite initiations and Phase 3 enrollment are progressing slower than expected due to a variety of factors, including federal government-associated budget cuts affecting some institutions.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.38 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $59.66M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Mar 05, 2026 which is in 91 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on Nov 12, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.125 by $0.015.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.08.
How many shares outstanding does Talphera have?
Talphera has 46,609,620 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.125. Following the earnings report the stock price went down -18.605%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.25 (150.00% Upside)
$3.25 (150.00% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
-86.48%
Trailing 12-Months
Asset Growth
-33.56%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
TLPH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative aspects. While there are significant achievements in financial stability, regulatory clarity, and enrollment progress, the delays in site activation and enrollment challenges pose notable concerns.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.25
▲(150.00% Upside)
Technical Analysis
Ownership Overview
5.73% Insiders
0.49% Mutual Funds
37.20% Other Institutional Investors
56.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---